• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在年龄相关性黄斑变性治疗试验的比较中,由眼科治疗医生与一个阅读中心通过光学相干断层扫描识别液体。

IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.

作者信息

Toth Cynthia A, Decroos Francis Char, Ying Gui-Shuang, Stinnett Sandra S, Heydary Cynthia S, Burns Russell, Maguire Maureen, Martin Daniel, Jaffe Glenn J

机构信息

*Duke University Eye Center, Department of Ophthalmology, Durham, North Carolina; †Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania; and ‡Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.

出版信息

Retina. 2015 Jul;35(7):1303-14. doi: 10.1097/IAE.0000000000000483.

DOI:10.1097/IAE.0000000000000483
PMID:26102433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4479420/
Abstract

PURPOSE

To examine treatment decisions by ophthalmologists versus reading center fluid identification from optical coherence tomography in Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

METHODS

Fluid in 6,210 optical coherence tomography scans (598 patients) in "as needed treatment" arm of CATT Year 1 was compared with ophthalmologist's treatment: positive fluid agreement (PFA, fluid+, treatment+) and positive fluid discrepancy (PFD, fluid+, treatment-), negative fluid agreement (fluid-, treatment-) and negative fluid discrepancy (fluid-, treatment+). For PFDs, fluid location and visual acuity were characterized.

RESULTS

Treatment and reading center fluid determination agreed in 72.1% (53.0% PFA, 19.1% negative fluid agreement) and disagreed in 27.9% (25.7% PFD, 2.2% negative fluid discrepancy) of visits, with no discrepancies for 20.9% of patients. Compared with PFA, PFD occurred more commonly with lower total foveal thickness (mean ± SD: 265 ± 103 PFD, 366 ± 151 μm PFA), presence of intraretinal fluid only, smaller fluid areas (PFA areas greater than twice those of PFD, P < 0.001), and greater decrease in retinal and lesion thickness. Mean acuities before, at, and after PFD were 65.8, 66.9, and 66.3 letters.

CONCLUSION

Treatment decisions by ophthalmologists matched reading center fluid determination in the majority of visits. More pronounced response to treatment and smaller foci of fluid likely contributed to PFD. Positive fluid discrepancy did not have substantial impact on subsequent visual acuity.

摘要

目的

在年龄相关性黄斑变性治疗试验比较(CATT)中,比较眼科医生的治疗决策与光学相干断层扫描阅读中心对液体的识别情况。

方法

将CATT研究第1年“按需治疗”组中6210次光学相干断层扫描(598例患者)中的液体情况与眼科医生的治疗情况进行比较:液体阳性一致性(PFA,液体阳性、治疗阳性)、液体阳性差异(PFD,液体阳性、治疗阴性)、液体阴性一致性(液体阴性、治疗阴性)和液体阴性差异(液体阴性、治疗阳性)。对于PFD情况,对液体位置和视力进行了特征描述。

结果

在72.1%的就诊中,治疗与阅读中心对液体的判定一致(53.0%为PFA,19.1%为液体阴性一致性),27.9%不一致(25.7%为PFD,2.2%为液体阴性差异),20.9%的患者无差异。与PFA相比,PFD更常见于总黄斑中心凹厚度较低时(均值±标准差:PFD为265±103μm,PFA为366±151μm)、仅存在视网膜内液体时、液体区域较小(PFA区域大于PFD区域的两倍,P<0.001)以及视网膜和病变厚度下降更大时。PFD发生前、发生时和发生后的平均视力分别为65.8、66.9和66.3字母。

结论

在大多数就诊中,眼科医生的治疗决策与阅读中心对液体的判定相符。对治疗更明显的反应和较小的液体病灶可能导致了PFD。液体阳性差异对后续视力没有实质性影响。

相似文献

1
IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.在年龄相关性黄斑变性治疗试验的比较中,由眼科治疗医生与一个阅读中心通过光学相干断层扫描识别液体。
Retina. 2015 Jul;35(7):1303-14. doi: 10.1097/IAE.0000000000000483.
2
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.五年期年龄相关性黄斑变性治疗试验比较的黄斑形态和视力。
Ophthalmology. 2019 Feb;126(2):252-260. doi: 10.1016/j.ophtha.2018.08.035. Epub 2018 Sep 3.
3
CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.光学相干断层扫描高反射灶与新生血管性年龄相关性黄斑变性及息肉样脉络膜血管病变抗VEGF治疗后视觉预后的相关性
Retina. 2016 Mar;36(3):465-75. doi: 10.1097/IAE.0000000000000645.
4
INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.玻璃体内注射阿柏西普治疗对雷珠单抗治疗无反应的年龄相关性黄斑变性所致脉络膜新生血管
Retina. 2016 Apr;36(4):770-7. doi: 10.1097/IAE.0000000000000751.
5
PREDICTING RESPONSE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION TO BEVACIZUMAB BASED ON SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY.基于谱域光学相干断层扫描预测渗出性年龄相关性黄斑变性对贝伐单抗的反应
Retina. 2016 Feb;36(2):259-63. doi: 10.1097/IAE.0000000000000690.
6
Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration.三维定量视网膜内及视网膜下液与新生血管性年龄相关性黄斑变性视力的相关性
JAMA Ophthalmol. 2016 Feb;134(2):182-90. doi: 10.1001/jamaophthalmol.2015.4948.
7
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.雷珠单抗与贝伐单抗治疗新生血管性年龄相关性黄斑变性的比较:来自 GEFAL 非劣效性随机试验的结果。
Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.
8
INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).玻璃体黄斑界面在采用治疗与延长治疗方案治疗年龄相关性黄斑变性(VINTREX)中对抗血管内皮生长因子治疗的影响
Retina. 2015 Sep;35(9):1757-64. doi: 10.1097/IAE.0000000000000663.
9
REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性时的难治性视网膜内或视网膜下液:功能和结构结果
Retina. 2015 Jun;35(6):1195-201. doi: 10.1097/IAE.0000000000000465.
10
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.阿柏西普治疗对贝伐单抗和雷珠单抗抵抗的渗出性年龄相关性黄斑变性。
Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.

引用本文的文献

1
Human expert grading versus automated quantification of fluid volumes in nAMD, DME and BRVO.湿性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜分支静脉阻塞中人工专家分级与液体体积自动定量分析的比较
Sci Rep. 2025 Aug 19;15(1):30414. doi: 10.1038/s41598-025-13019-x.
2
Imaging biomarkers and artificial intelligence for diagnosis, prediction, and therapy of macular fibrosis in age-related macular degeneration: Narrative review and future directions.用于年龄相关性黄斑变性中黄斑纤维化诊断、预测和治疗的影像生物标志物与人工智能:叙述性综述及未来方向
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 10. doi: 10.1007/s00417-025-06790-0.
3
Comparison of AI-based retinal fluid monitoring in neovascular age-related macular degeneration with manual assessment by different eye care professionals under optimized conditions.在优化条件下,对基于人工智能的新生血管性年龄相关性黄斑变性视网膜积液监测与不同眼科护理专业人员的手动评估进行比较。
Acta Ophthalmol. 2025 Aug;103(5):552-560. doi: 10.1111/aos.17458. Epub 2025 Feb 14.
4
Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2-Artificial Intelligence Analytics.自我给药光学相干断层扫描在新生血管性年龄相关性黄斑变性中有效性的关键试验。报告2-人工智能分析
Ophthalmol Sci. 2024 Nov 26;5(2):100662. doi: 10.1016/j.xops.2024.100662. eCollection 2025 Mar-Apr.
5
Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study.基于人工智能的疾病活动监测用于个性化新生血管性年龄相关性黄斑变性治疗:一项可行性研究。
Ophthalmol Sci. 2024 Jun 17;4(6):100565. doi: 10.1016/j.xops.2024.100565. eCollection 2024 Nov-Dec.
6
Quantifying Changes on OCT in Eyes Receiving Treatment for Neovascular Age-Related Macular Degeneration.量化接受治疗的新生血管性年龄相关性黄斑变性患者眼部的光学相干断层扫描变化。
Ophthalmol Sci. 2024 Jun 28;4(6):100570. doi: 10.1016/j.xops.2024.100570. eCollection 2024 Nov-Dec.
7
Performance of retinal fluid monitoring in OCT imaging by automated deep learning versus human expert grading in neovascular AMD.自动化深度学习与人类专家分级在新生血管性 AMD 的 OCT 成像中对视网膜液监测的性能比较。
Eye (Lond). 2023 Dec;37(18):3793-3800. doi: 10.1038/s41433-023-02615-8. Epub 2023 Jun 13.
8
A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices.使用多种设备对光学相干断层扫描生物标志物的人类专家一致性进行系统评价。
Eye (Lond). 2023 Aug;37(12):2573-2579. doi: 10.1038/s41433-022-02376-w. Epub 2022 Dec 28.
9
Prospective, Longitudinal Pilot Study: Daily Self-Imaging with Patient-Operated Home OCT in Neovascular Age-Related Macular Degeneration.前瞻性纵向试点研究:在新生血管性年龄相关性黄斑变性患者中使用患者操作的家用光学相干断层扫描进行每日自我成像。
Ophthalmol Sci. 2021 Jun 26;1(2):100034. doi: 10.1016/j.xops.2021.100034. eCollection 2021 Jun.
10
Automatic quantification of retinal photoreceptor integrity to predict persistent disease activity in neovascular age-related macular degeneration using deep learning.利用深度学习自动量化视网膜光感受器完整性以预测新生血管性年龄相关性黄斑变性的持续性疾病活动。
Front Neurosci. 2022 Aug 18;16:952735. doi: 10.3389/fnins.2022.952735. eCollection 2022.

本文引用的文献

1
Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.年龄相关性黄斑变性治疗试验比较中光学相干断层扫描评估的比较
Ophthalmology. 2014 Oct;121(10):1956-65. doi: 10.1016/j.ophtha.2014.04.020. Epub 2014 May 15.
2
Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.抗血管内皮生长因子治疗与未治疗的新生血管性年龄相关性黄斑变性患者脉络膜的增强深度成像。
Graefes Arch Clin Exp Ophthalmol. 2013 Jun;251(6):1483-8. doi: 10.1007/s00417-012-2199-x. Epub 2012 Nov 17.
3
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.抗血管内皮生长因子药物治疗新生血管性年龄相关性黄斑变性的一年视觉预后的基线预测因素。
Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.
4
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
5
Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.雷珠单抗灵活给药方案治疗新生血管性年龄相关性黄斑变性的安全性和有效性:SUSTAIN 研究。
Ophthalmology. 2011 Apr;118(4):663-71. doi: 10.1016/j.ophtha.2010.12.019.
6
A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.雷珠单抗治疗和延伸方案用于新生血管性年龄相关性黄斑变性的临床和经济影响。
Ophthalmology. 2010 Nov;117(11):2134-40. doi: 10.1016/j.ophtha.2010.02.032. Epub 2010 Jul 1.
7
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.雷珠单抗单药治疗渗出性年龄相关性黄斑变性的注射频率和视力结果评估。
Ophthalmology. 2009 Sep;116(9):1740-7. doi: 10.1016/j.ophtha.2009.05.033. Epub 2009 Jul 29.
8
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.雷珠单抗玻璃体腔内注射可变剂量方案治疗新生血管性年龄相关性黄斑变性:PrONTO研究的第2年
Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. doi: 10.1016/j.ajo.2009.01.024. Epub 2009 Apr 18.
9
Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab.频域与时域光学相干断层扫描在雷珠单抗治疗年龄相关性黄斑变性中的比较
Ophthalmology. 2009 May;116(5):947-55. doi: 10.1016/j.ophtha.2008.11.002. Epub 2009 Feb 20.
10
Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.雷珠单抗对年龄相关性黄斑变性所致黄斑中心凹下脉络膜新生血管患者的疗效
Am J Ophthalmol. 2009 May;147(5):831-7. doi: 10.1016/j.ajo.2008.12.005. Epub 2009 Feb 13.